Table: Taisho Pharmaceutical HD -Q1 group results
Aug 5 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2020 Jun 30, 2019 Mar 31, 2021
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 75.02 60.26 289.50
(+24.5 pct) (-2.4 pct) (+0.3 pct)
Operating 9.39 8.32 20.00
(+12.8 pct) (+2.0 pct) (-5.4 pct)
Recurring 11.12 7.65 23.00
(+45.3 pct) (-37.3 pct) (-6.0 pct)
Net 6.06 11.01 13.00
(-44.9 pct) (-19.6 pct) (-35.6 pct)
EPS 75.98 yen 137.91 yen 162.89 yen
EPS Diluted 75.89 yen 137.77 yen
Ann Div 110.00 yen 100.00 yen
-Q2 div 50.00 yen 50.00 yen
-Q4 div 60.00 yen 50.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10